Zhang, X., Jia, J., Lu, M., Wang, X., Gong, J., Li, J., . . . Shen, L. (2019). Nimotuzumab Plus Paclitaxel and Cisplatin as a 1(st)-Line Treatment for Esophageal Cancer: Long Term Follow-up of a Phase II Study. J Cancer.
シカゴスタイル引用形Zhang, Xiaodong, et al. "Nimotuzumab Plus Paclitaxel and Cisplatin As a 1(st)-Line Treatment for Esophageal Cancer: Long Term Follow-up of a Phase II Study." J Cancer 2019.
MLA引用形式Zhang, Xiaodong, et al. "Nimotuzumab Plus Paclitaxel and Cisplatin As a 1(st)-Line Treatment for Esophageal Cancer: Long Term Follow-up of a Phase II Study." J Cancer 2019.
警告: この引用は必ずしも正確ではありません.